BUSINESSQUARTZ
Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline overhaul
Sanofi is discontinuing its eczema drug as part of a CEO-led pipeline overhaul, citing insufficient improvement over existing treatments like its own Dupixent.
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
- STAT+: Allogene CEO David Chang stepping down
- STAT+: FDA approves Sanofi diabetes drug for children with stage 3 diabetes
- STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more